Access content directly

Maël Heiblig

45
Documents

Publications

Deep Learning‐Based Blood Abnormalities Detection as a Tool for VEXAS Syndrome Screening

Cédric de Almeida Braga , Maxence Bauvais , Pierre Sujobert , Maël Heiblig , Maxime Jullien
International Journal of Laboratory Hematology, 2024, ⟨10.1111/ijlh.14368⟩
Journal articles hal-04778186v1

Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry

Benjamin de Valence , Marion Delaune , Yann Nguyen , Vincent Jachiet , Mael Heiblig
Annals of the Rheumatic Diseases, 2024, 83 (3), pp.372-381. ⟨10.1136/ard-2023-224819⟩
Journal articles hal-04888392v1
Image document

Efficacy and safety of mammalian target of rapamycin inhibitors in systemic mastocytosis: A nationwide French pilot study.

Josquin Moraly , Julien Rossignol , Claire Rouzaud , Thomas Gabas , Hassiba Bouktit
American Journal of Hematology, 2024, American Journal of Hematology, 99 (6), pp.1095-1102. ⟨10.1002/ajh.27323⟩
Journal articles hal-04691823v1
Image document

Histological characterization of liver involvement in systemic mastocytosis.

Julien Rossignol , Danielle Canioni , Achille Aouba , Cristina Bulai-Livideanu , Stéphane Barete
Liver International, 2024, Liver International, 44 (7), pp.1680-1688. ⟨10.1111/liv.15913⟩
Journal articles hal-04685730v1
Image document

Human myeloid differentiation by BMP4 signaling through the VDR pathway in acute myeloid leukemia

Florence Zylbersztejn , Iryna Byelinska , Sandrine Jeanpierre , Léa Barral , Kevin Geistlich
Cell Death Discovery, 2024, 10, ⟨10.1038/s41420-024-02090-4⟩
Journal articles hal-04675664v1
Image document

Comparison of prognostic scores according to WHO classification in 170 patients with advanced mastocytosis and C‐finding treated with midostaurin

Maël Heiblig , Clément Gourguechon , Philippe Guilpain , Cristina Bulai-Livideanu , Stéphane Barete
American Journal of Hematology, 2024, 99 (11), pp.2127-2139. ⟨10.1002/ajh.27478⟩
Journal articles inserm-04902870v1

Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX

Jerome Hadjadj , Yann Nguyen , Dalila Mouloudj , Rim Bourguiba , Mael Heiblig
Annals of the Rheumatic Diseases, 2024, pp.ard-2024-225640. ⟨10.1136/ard-2024-225640⟩
Journal articles hal-04711359v1
Image document

Allogeneic Hematopoietic Cell Transplantation for VEXAS Syndrome: Results of a Multicenter Study of the EBMT.

Carmelo Gurnari , Linda Koster , Laurien Baaij , Mael Heiblig , Ibrahim Yakoub-Agha
Blood Advances, 2024, Blood Advances, 8, pp.1444-1448. ⟨10.1182/bloodadvances.2023012478⟩
Journal articles hal-04672729v1
Image document

Nonischemic Cardiac Manifestations in VEXAS Syndrome

Marie Robert , Alexis Mathian , Valentin Lacombe , Hervé Lobbes , Léopold Adélaïde
JAMA Network Open, 2024, 7 (12), pp.e2450251. ⟨10.1001/jamanetworkopen.2024.50251⟩
Journal articles hal-04888717v1

LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study

Loic Vasseur , Laurène Fenwarth , Jérôme Lambert , Stéphane de Botton , Martin Figeac
Blood Advances, 2023, 7 (15), pp.4024-4034. ⟨10.1182/bloodadvances.2023010155⟩
Journal articles hal-04106615v1

Mutational Profile and Dynamics of PPM1D -Mutant Clones in the Spectrum of Myeloid Disorders

Jean Pegliasco , David Fandrei , Florence Pasquier , Nathalie Ibrahim , Maria Kfoury
Blood, 2023, 142 (Supplement 1), pp.4064-4064. ⟨10.1182/blood-2023-189428⟩
Journal articles hal-04356640v1

VEXAS: where do we stand 2 years later?

Pierre Sujobert , Maël Heiblig , Yvan Jamilloux
Current Opinion in Hematology, 2023, 30 (2), pp.64-69. ⟨10.1097/MOH.0000000000000750⟩
Journal articles hal-04906810v1

Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: A multicenter retrospective study of 59 cases

Ève Zakine , Loula Papageorgiou , Rim Bourguiba , Arsène Mekinian , Benjamin Terrier
Journal of The American Academy of Dermatology, 2023, 88 (4), pp.917-920. ⟨10.1016/j.jaad.2022.10.052⟩
Journal articles hal-04193759v1

From vacuoles to VEXAS

Maël Heiblig , Pierre Sujobert
Rheumatology, 2023, 62 (12), pp.3780-3781. ⟨10.1093/rheumatology/kead392⟩
Journal articles hal-04906677v1

Chronic myelomonocytic leukemia transdifferentiation landscape: From histiocytosis to blastic plasmacytoid dendritic cell neoplasm

Gabriel Antherieu , Marie Donzel , Brigitte Balme , Alexandra Traverse-Glehen , Maël Heiblig
American Journal of Hematology, 2023, 98 (8), pp.1343-1345. ⟨10.1002/ajh.26876⟩
Journal articles hal-04906261v1

Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33 Positive Acute Myeloid Leukemia: Results from a French Retrospective Observational Study

Juliette Lambert , Emmanuel Raffoux , Delphine Lebon , Thorsten Braun , Mael Heiblig
Blood, 2023, 142 (Supplement 1), pp.2893-2893. ⟨10.1182/blood-2023-179575⟩
Journal articles hal-04355381v1

Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression

Eytan Stein , Stephane de Botton , Thomas Cluzeau , Arnaud Pigneux , Jane Liesveld
Leukemia & lymphoma, 2023, pp.1-10. ⟨10.1080/10428194.2023.2243356⟩
Journal articles hal-04182855v1

Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study

Grégoire Le Meur , Adriana Plesa , Marie-Virginie Larcher , Gaëlle Fossard , Fiorenza Barraco
Transplantation and Cellular Therapy, 2023, 29 (1), pp.38.e1-38.e9. ⟨10.1016/j.jtct.2022.09.003⟩
Journal articles hal-04906736v1
Image document

Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO

Pierre-Yves Dumas , Emmanuel Raffoux , Emilie Bérard , Sarah Bertoli , Marie-Anne Hospital
Leukemia, 2023, 37 (1), pp.91-101. ⟨10.1038/s41375-022-01742-7⟩
Journal articles hal-04244552v1

Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry.

Benjamin de Valence , Marion Delaune , Yann Nguyen , Vincent Jachiet , Mael Heiblig
Annals of the Rheumatic Diseases, 2023, Annals of the Rheumatic Diseases, ⟨10.1136/ard-2023-224819⟩
Journal articles hal-04519630v1

Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes

Laura Polivka , Marine Madrange , Cristina Bulai-Livideanu , Stéphane Barete , Thomas Ballul
Journal of Allergy and Clinical Immunology, 2023, ⟨10.1016/j.jaci.2023.08.015⟩
Journal articles hal-04339470v1

Impact of Arsenic Trioxide in the Treatment of Higher Risk Acute Promyelocytic Leukemia

Audrey da Rocha , Bruno Cassinat , Mael Heiblig , Christian Recher , Sarah Bertoli
Blood, 2023, 142 (Supplement 1), pp.1471-1471. ⟨10.1182/blood-2023-174446⟩
Journal articles hal-04355510v1

Deep Learning Based Blood Abnormalities Detection As a Tool for Vexas Syndrome Screening

Cedric de Almeida Braga , Maxence Bauvais , Pierre Sujobert , Mael Heiblig , Maxime Jullien
Blood, 2023, 142 (Supplement 1), pp.3648-3648. ⟨10.1182/blood-2023-186874⟩
Journal articles hal-04456433v1

C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3 -Mutant Leukemia

Marie Sabatier , Rudy Birsen , Laura Lauture , Sarah Mouche , Paolo Angelino
Cancer Discovery, 2023, 13 (7), pp.1720-1747. ⟨10.1158/2159-8290.CD-22-0411⟩
Journal articles hal-04166110v1

Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trials

Xavier Thomas , Mohamed Elhamri , Alexandre Deloire , Maël Heiblig
Expert Opinion on Emerging Drugs, 2022, 27 (2), pp.169-185. ⟨10.1080/14728214.2022.2094365⟩
Journal articles hal-04907717v1

Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group

Elise Fournier , Maël Heiblig , Christine Lespinasse , Pascale Flandrin-Gresta , Antoine Geay
Leukemia, 2022, 36 (5), pp.1390-1400. ⟨10.1038/s41375-022-01534-z⟩
Journal articles hal-04907143v1

Diagnosis of acute promyelocytic leukemia based on routine biological parameters using machine learning

Estelle Cheli , Simon Chevalier , Olivier Kosmider , Marion Eveillard , Nicolas Chapuis
Haematologica, 2022, 107 (6), pp.1466-1469. ⟨10.3324/haematol.2022.280406⟩
Journal articles hal-04907070v1

Pleuropulmonary manifestations of VEXAS syndrome

Raphael Borie , Marie-Pierre Debray , Alexis F. Guedon , Arsène Mekinian , Louis Terriou
Chest, 2022, Chest, 163 (3), pp.575-585. ⟨10.1016/j.chest.2022.10.011⟩
Journal articles hal-04498358v1

Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters

Peter-Martin Bruch , Sascha Dietrich , Herve Finel , Ariane Boumendil , Hildegard Greinix
Leukemia, 2022, 37 (2), pp.465-472. ⟨10.1038/s41375-022-01782-z⟩
Journal articles hal-04922926v1
Image document

Class I/Class II HLA Evolutionary Divergence Ratio Is an Independent Marker Associated With Disease-Free and Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

Anne-Marie Daull , Valérie Dubois , Hélène Labussière-Wallet , Fabienne Venet , Fiorenza Barraco
Frontiers in Immunology, 2022, 13, pp.841470. ⟨10.3389/fimmu.2022.841470⟩
Journal articles inserm-04010303v1

Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study

Maël Heiblig , Marcela Ferrada , Matthew Koster , Thomas Barba , Mathieu Gerfaud-Valentin
Blood, 2022, 140 (8), pp.927-931. ⟨10.1182/blood.2022016642⟩
Journal articles hal-04907677v1

How to Transform an Exceptional Case Report Into a Therapy: Following the Frog Out of the Box

Maël Heiblig , Vincent Alcazer , Adriana Plesa , Hélène Labussière-Wallet , Pierre Sujobert
HemaSphere, 2021, 5 (9), pp.e629. ⟨10.1097/HS9.0000000000000629⟩
Journal articles hal-04908718v1
Image document

Chronic T cell receptor stimulation unmasks NK receptor signaling in peripheral T cell lymphomas via epigenetic reprogramming

Sylvain Carras , Dimitri Chartoire , Sylvain Mareschal , Maël Heiblig , Antoine Marçais
The Journal of clinical investigation, 2021, 131 (13), pp.e139675. ⟨10.1172/jci139675⟩
Journal articles inserm-03280949v1

Toward a pathophysiology inspired treatment of VEXAS syndrome

Maël Heiblig , Bhavisha Patel , Emma Groarke , Estelle Bourbon , Pierre Sujobert
Seminars in Hematology, 2021, 58 (4), pp.239-246. ⟨10.1053/j.seminhematol.2021.09.001⟩
Journal articles hal-04908739v1

Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry

Thibault Comont , Mael Heiblig , Etienne Riviere , Louis Terriou , Julien Rossignol
British Journal of Haematology, 2021, British Journal of Haematology, -, ⟨10.1111/bjh.17893⟩
Journal articles hal-04481451v1
Image document

Performances of Targeted RNA Sequencing for the Analysis of Fusion Transcripts, Gene Mutation, and Expression in Hematological Malignancies

Sandrine Hayette , Béatrice Grange , Maxime Vallee , Claire Bardel , Sarah Huet
HemaSphere, 2021, 5 (2), pp.e522. ⟨10.1097/HS9.0000000000000522⟩
Journal articles hal-04382990v1

Therapeutic options in VEXAS syndrome: insights from a retrospective series

Estelle Bourbon , Maël Heiblig , Mathieu Gerfaud Valentin , Thomas Barba , Cécile-Audrey Durel
Blood, 2021, 137 (26), pp.3682-3684. ⟨10.1182/blood.2020010177⟩
Journal articles hal-04908402v1
Image document

The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively

Mael Heiblig , Nicolas Duployez , Alice Marceau , Delphine Lebon , Laure Goursaud
Cancers, 2021, 13 (9), ⟨10.3390/cancers13092156⟩
Journal articles hal-03606391v1

Allogenic Stem Cell Transplantation Abrogates Negative Impact on Outcome of AML Patients with KMT2A Partial Tandem Duplication

Gabriel Antherieu , Audrey Bidet , Sarah Huet , Sandrine Hayette , Marina Migeon
Cancers, 2021, 13 (9), pp.2272. ⟨10.3390/cancers13092272⟩
Journal articles hal-04908304v1
Image document

Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively

Maël Heiblig , Nicolas Duployez , Alice Marceau , Delphine Lebon , Laure Goursaud
Blood, 2020, 136 (1), ⟨10.1182/blood-2020-141890⟩
Journal articles hal-03606389v1

Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RAR alpha Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

Eytan M. Stein , Stephane de Botton , Thomas Cluzeau , Arnaud Pigneux , Jane L. Liesveld
Blood, 2020, 136 (1), ⟨10.1182/blood-2020-134602⟩
Journal articles hal-03606393v1

Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience

Maël Heiblig , Hélène Labussière-Wallet , Franck Emmanuel Nicolini , Mauricette Michallet , Sandrine Hayette
Cancers, 2019, 11 (4), pp.570. ⟨10.3390/cancers11040570⟩
Journal articles hal-04908088v1

Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study

Maël Heiblig , Delphine Rea , Marie-Lorraine Chrétien , Aude Charbonnier , Philippe Rousselot
Experimental Hematology, 2018, 67, pp.41 - 48. ⟨10.1016/j.exphem.2018.08.006⟩
Journal articles hal-01927788v1

The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment

Xavier Thomas , Maël Heiblig
Expert Opinion on Drug Discovery, 2016, 11 (11), pp.1061-1070. ⟨10.1080/17460441.2016.1227318⟩
Journal articles hal-01796194v1